Masimo (MASI) AI Stock Analysis

• Market Cap: $7.29B
• Dividend Yield: N/A
• Average Volume (3M): 740.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.94
• Revenue Growth: -16.03%
• EPS Growth: -813.48%
• Country: US
• Employees: 3,600
• Sector: N/A
• Sector Strength: N/A
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.32
• Shares Outstanding: 53,713,947
• 10 Day Avg. Volume: 1,030,492
• 30 Day Avg. Volume: 740,686
• PEG Ratio: 0.06
• Price to Book (P/B): 8.66
• Price to Sales (P/S): 4.35
• P/FCF Ratio: 51.66
• Enterprise Value/Market Cap: 1.09
• Enterprise Value/Revenue: 4.64
• Enterprise Value/Gross Profit: 8.45
• Enterprise Value/Ebitda: -111.85
• 1Y Price Target: $161.00
• Price Target Upside: 13.27% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $145.00 ▲(2.01% Upside)

Masimo's overall stock score reflects significant financial challenges, with declining revenues and profitability being the most impactful factors. Despite this, strategic corporate events and positive earnings call highlights provide some optimism for future growth and operational improvements.

Masimo Business Overview & Revenue Model

Company Description

Masimo Corporation (MASI) is a global medical technology company that develops innovative non-invasive monitoring solutions to improve patient outcomes. Founded in 1989, Masimo specializes in advanced non-invasive monitoring technologies, particularly in the areas of pulse oximetry and brain function monitoring. The company serves a variety of sectors including hospitals, surgical centers, and home care, offering a range of products that include non-invasive sensors, monitoring devices, and advanced software solutions.

How the Company Makes Money

Masimo generates revenue primarily through the sale of its medical devices, sensors, and related consumables. The company's key revenue streams include the sale of proprietary pulse oximetry devices and sensors, which are utilized in hospitals and other healthcare facilities to measure blood oxygen levels and other vital signs. Additionally, Masimo benefits from recurring revenue through the sale of single-use sensors that require regular replacement, creating a consistent income stream. The company also earns revenue from software solutions that enhance monitoring capabilities and improve clinical decision-making. Significant partnerships with healthcare providers and integration of its technologies into various medical systems further contribute to Masimo's earnings, as they expand the reach of its products and enhance clinical workflow efficiency.

Masimo Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Masimo Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 142.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MASI, the sentiment is Negative. The current price of 142.14 is above the 20-day moving average (MA) of 141.32, below the 50-day MA of 144.61, and below the 200-day MA of 153.89, indicating a bearish trend. The MACD of -2.37 indicates Positive momentum. The RSI at 39.65 is Neutral, neither overbought nor oversold. The STOCH value of 14.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MASI.

Masimo Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
HAE	70 Outperform	$3.74B	23.31	19.47%	―	-2.45%	41.50%
HOLX	69 Neutral	$16.71B	30.18	11.12%	―	1.74%	-25.29%
MMSI	68 Neutral	$5.17B	44.77	8.30%	―	11.49%	-2.89%
TFX	68 Neutral	$5.53B	―	-7.90%	1.09%	5.43%	-245.18%
ATR	60 Neutral	$8.11B	19.81	15.80%	1.48%	2.50%	25.05%
MASI	54 Neutral	$7.29B	-12.88	-17.93%	―	-16.03%	-813.48%

Masimo Corporate Events

Masimo Unveils Long-Term Strategy at Investor Day

On December 3, 2025, Masimo Corporation held its 2025 Investor Day, where CEO Katie Szyman and other executives presented the company’s long-term strategy and financial targets. The company reaffirmed its 2025 financial guidance and announced ambitious growth targets through 2028, including a revenue CAGR of 7%-10%, operating margin of 30%, and cumulative operating cash flow of approximately $1 billion from 2026-2028. Masimo emphasized its focus on patient outcomes, technology innovation, and commercial execution as key pillars for future growth.

Masimo Secures New $1 Billion Credit Facility

On December 1, 2025, Masimo Corporation successfully refinanced its credit obligations by terminating its previous credit agreement and entering into a new Credit Facility. The new agreement includes a $250 million unsecured term loan and $750 million in revolving commitments, with the potential to increase borrowing capacity by an additional $400 million. This strategic financial move is expected to support Masimo’s general corporate purposes, capital investment, and working capital needs, potentially strengthening its financial stability and operational flexibility.

Masimo Reports Strong Q3 2025 Financial Results

On November 4, 2025, Masimo Corporation announced its financial results for the third quarter of 2025, reporting a GAAP revenue of $371.5 million, an 8.2% increase, and a non-GAAP net income per diluted share growth of 38% compared to the previous year. The company highlighted its strategic moves, including the sale of Sound United and an expanded partnership with Philips, positioning itself for sustainable long-term growth.

Masimo Sells Sound United to HARMAN for $328M

On September 23, 2025, Masimo completed the sale of its consumer audio business, Sound United, to HARMAN International for approximately $328 million in cash. This transaction marks a strategic move for Masimo to focus on its core professional healthcare business, with plans to use the proceeds for share repurchases, thereby enhancing growth and delivering stronger margins.